STOCK TITAN
  1. Home
  2. News
  3. PSNL

Personalis, Inc. - PSNL STOCK NEWS

Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.

Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.

Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.

Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.

Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.

For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.

News

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay, providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries. NeXT Dx analyzes a tumor’s entire exome and transcriptome to uncover deeper insights into therapy selection, including RNA-based fusions, tumor mutational burden, and microsatellite instability. The coverage for NeXT DX was extended effective August 29, 2023, under the Palmetto GBA MolDx program foundational Local Coverage Determination. Approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare. Personalis also recently launched the ultra-sensitive NeXT Personal Dx test for detecting molecular residual disease and cancer recurrence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
none
-
News

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Rhea-AI Summary
Personalis, Inc. (PSNL) Reports Strong Revenue Growth and Cash Balance Increase in Preliminary Fourth Quarter and Full Year 2023 Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
none
-
News

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) has announced a reduction in headcount impacting approximately 20% of the company’s staff, expected to reduce operating expenses by approximately $14 million annually. The company also disclosed a recent strategic collaboration with Tempus, expected to extend the cash position of the company into 2026. The collaboration with Tempus includes the exclusive relationship with one of the largest oncology testing labs in the U.S., providing additional capital for Personalis to continue developing clinical evidence to achieve reimbursement while working closely with Tempus to provide oncologists and their patients with much greater access to the NeXT Personal Dx ultra-sensitive MRD test. The company also provided warrants to Tempus to purchase approximately 9.2 million shares of the company’s common stock at an average price of $2/share, potentially providing approximately $30 million to the company exclusive of any payments to Tempus for the fair market value of sales, marketing, and sample logistics services. Personalis is targeting aggressive goals in 2024, including developing clinical evidence across ~10 clinical studies, progressing toward long-term goal of achieving 60%-plus gross margins, and driving early commercial success for NeXT Personal Dx with Tempus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.8%
Tags
none
News

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Rhea-AI Summary
Personalis, Inc. (PSNL) and Tempus Labs, Inc. announced a strategic collaboration to co-commercialize NeXT Personal® Dx, a whole genome-based liquid biopsy laboratory developed test for detection of molecular residual disease (MRD) and recurrence in cancer. The test, launched in October, sets a new standard in MRD tests with unprecedented sensitivity and high specificity. The collaboration focuses on tumor-informed MRD testing for lung cancer, breast cancer, and immunotherapy monitoring after clinical validation, with the potential to test tens of thousands of new patients over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
News

Personalis Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Personalis, Inc. (PSNL) reports 23% increase in Q3 revenue to $18.2 million. NeXT Personal's clinical data shows higher sensitivity for cancer recurrence detection, up to 4x higher than other tests. Full year guidance increased to $73-74 million total revenue and net loss of $103 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.5%
Tags
earnings
-
News

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Rhea-AI Summary
Personalis, Inc. has launched the Early Access Program for NeXT Personal Dx, a tumor-informed liquid biopsy test for detecting molecular residual disease and cancer recurrence. The test offers unprecedented sensitivity and specificity, detecting down to 1 PPM tumor fraction and achieving over 99.9% analytical specificity. NeXT Personal Dx is currently available to a limited number of clinical customers, with a focus on lung cancer, breast cancer, and immunotherapy response monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
News

Personalis to Announce Third Quarter 2023 Financial Results

Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) will release its Q3 2023 financial results on November 7, 2023. The company will host a conference call and webcast to discuss the results and recent highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.41%
Tags
earnings
-
News

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

Rhea-AI Summary
Personalis announces improved detection rates for early-stage lung cancer with its NeXT Personal ctDNA assay
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

Rhea-AI Summary
Personalis to present data on its NeXT Personal® assay at the 2023 ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
News

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Rhea-AI Summary
Personalis appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance and achieves ISO 13485:2016 certification
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
management

FAQ

What is the current stock price of Personalis (PSNL)?

The current stock price of Personalis (PSNL) is $5.75 as of December 20, 2024.

What is the market cap of Personalis (PSNL)?

The market cap of Personalis (PSNL) is approximately 474.6M.

What does Personalis, Inc. specialize in?

Personalis, Inc. specializes in genome-scale diagnostics and genome-guided medicine.

What are Personalis' main products?

Their main products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test.

Who can benefit from Personalis' services?

Academic, pharmaceutical, and biotech researchers engaged in genome studies, pharmacogenomics, and cancer research can benefit from their services.

What technologies does Personalis use?

Personalis uses whole genome and exome sequencing, proprietary databases, human reference sequences, and sophisticated algorithms.

What is the mission of Personalis, Inc.?

The mission of Personalis is to pioneer genome-guided medicine by obtaining accurate genetic data and drawing reliable, medically-focused conclusions.

How does Personalis support cancer research?

Personalis provides genomic sequencing and analytics solutions that support the development of personalized cancer vaccines and next-generation cancer immunotherapies.

What recent achievements has Personalis made?

Personalis has formed key partnerships with pharmaceutical companies to advance personalized cancer treatments.

What sets Personalis apart from other genomic companies?

Personalis' comprehensive end-to-end genome sequencing and analysis solutions, coupled with their proprietary technologies, set them apart.

Why is genome sequencing important in medical research?

Genome sequencing is crucial for understanding genetic factors in diseases, enabling the development of targeted treatments and personalized medicine.

How can I stay updated on Personalis' latest news?

You can stay updated on Personalis' latest news by following their updates on StockTitan and other financial news platforms.

Stock PSNL logo
Personalis, Inc.

Nasdaq:PSNL

PSNL Rankings

#3144 Ranked by Market Cap
N/A Ranked by Dividends

PSNL Stock Data

474.58M
54.05M
19.3%
53.16%
4.04%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT